A randomized control study by Nobili et al. [64] reported that docosahexaenoic acid taken orally for 6 months reduced liver fat content and improved insulin sensitivity in children with NAFLD. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.